Cancer Immunotherapy: Recent Advances and Challenges

Posted On 2021-07-07 13:32:51

In this focused series, we celebrate the success of T-cell targeted agents and provide a comprehensive overview of challenges with cancer immunotherapy. Discussed topics include immune-related adverse events and financial toxicities, safety concerns in patients with pre-existing immune dysfunction, current and emerging biomarkers of response along with a detailed discussion on the role of the gut microbiome in modulating response to ICI. Other reviewed topics include chimeric antigen receptor T-cell (CAR T-cell) therapy and ICI in lymphoid malignancies, clinical studies exploring ways to turn immunologically inert “cold” sarcomas “hot’’ and intralesional agents in the treatment of malignant melanoma.

Cancer immunotherapy: recent advances and challenges
Umang Swami, Mohammed Milhem

Original Article
Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
Swetha Alexander, Umang Swami, Aneet Kaur, Yubo Gao, Munazza Fatima, Meredith M. Ginn, Jill E. Stein, Petros Grivas, Yousef Zakharia, Namrata Singh

Review Article
The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
Abdul Rafeh Naqash, Alba J. Kihn-Alarcón, Chara Stavraka, Kathleen Kerrigan, Saman Maleki Vareki, David James Pinato, Sonam Puri

Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
Vaia Florou, Sonam Puri, Ignacio Garrido-Laguna, Breelyn A. Wilky

CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
Mayur Narkhede, Amitkumar Mehta, Stephen M. Ansell, Gaurav Goyal

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
Haris Hatic, Devi Sampat, Gaurav Goyal

Current status of intralesional agents in treatment of malignant melanoma
Misam Zawit, Umang Swami, Hassan Awada, Joyce Arnouk, Mohammed Milhem, Yousef Zakharia

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
Jeff Rytlewski, Mohammed M. Milhem, Varun Monga

Biomarkers of therapeutic response with immune checkpoint inhibitors
Poorva Bindal, Jhanelle E. Gray, Theresa A. Boyle, Vaia Florou, Sonam Puri

The dark side of immunotherapy
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, Kenneth F. Grossmann, Umang Swami

The focused issue “Cancer Immunotherapy: Recent Advances and Challenges” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Umang Swami and Mohammed Milhem are serving as the unpaid Guest Editors for the focused issue.